Newborn screening for SMA often uses real-time quantitative polymerase chain reaction (qRT-PCR) techniques to assess the patient’s SMN genes, using DNA isolated from dried blood spots (DBSs) collected soon after birth. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.